Mymd Pharmaceuticals (NASDAQ:QCLS) Announces Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS) announced its quarterly earnings data on Wednesday. The company reported ($0.79) EPS for the quarter, Zacks reports.

Mymd Pharmaceuticals Stock Performance

Shares of Mymd Pharmaceuticals stock traded down $0.09 on Friday, reaching $2.77. 78,880 shares of the stock were exchanged, compared to its average volume of 666,976. The stock has a market cap of $11.53 million, a price-to-earnings ratio of -0.13 and a beta of 2.16. The firm’s 50 day simple moving average is $3.46. Mymd Pharmaceuticals has a one year low of $2.50 and a one year high of $10.78.

Wall Street Analysts Forecast Growth

QCLS has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research report on Friday, August 7th. Wall Street Zen cut shares of Mymd Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.